Caris Life Sciences director granted 13,192 shares

Caris Life Sciences, Inc. reported that director Joseph E. Gilliam received an equity award in the form of 13,192 shares of Common Stock on 2026-08-14, recorded as a grant or award acquisition at no cash price per share.

Rhea-AI Filing Summary

Caris Life Sciences, Inc. reported that director Joseph E. Gilliam received an equity award in the form of 13,192 shares of Common Stock on 2026-08-14, recorded as a grant or award acquisition at no cash price per share. Following this award, his directly held position increased to 29,321 shares. A footnote explains that the award consists of restricted stock units that vest in accordance with the applicable grant agreement.

Insider Trade Summary

Grant/Award: 13,192 shares

Grant/Award 1 txn

Insider Gilliam Joseph E

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock F1	13,192	$0.00	$0.00

Holdings After Transaction: Common Stock — 29,321 shares (Direct)

Footnotes (1)

1. F1. Represents an award of restricted stock units which vest in accordance with the applicable grant agreement.

Key Figures

Shares awarded: 13,192 shares Per-share price: $0.0000 per share Shares owned after: 29,321 shares

3 metrics

Shares awarded 13,192 shares Grant or award acquisition of Common Stock on 2026-08-14

Per-share price $0.0000 per share Reported transaction price for the awarded shares

Shares owned after 29,321 shares Direct Common Stock holdings following the award

Key Terms

restricted stock units, grant, award, or other acquisition, direct ownership

3 terms

restricted stock units financial

"Represents an award of restricted stock units which vest in accordance"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

direct ownership financial

"ownership_type: direct, ownership_code: D"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Joseph E. Gilliam acquire in this Form 4 for CAI?

Joseph E. Gilliam received an equity award of 13,192 shares of Common Stock of Caris Life Sciences, Inc., reported as a grant or award acquisition rather than an open-market purchase.

What is Joseph E. Gilliam’s total CAI shareholding after this award?

After the reported award, Joseph E. Gilliam directly holds 29,321 shares of Caris Life Sciences, Inc. Common Stock. This figure reflects his post-transaction ownership as disclosed in the Form 4.

Was cash paid per share for the CAI stock granted to Joseph E. Gilliam?

No cash price was reported; the transaction lists a per-share price of $0.0000. The shares were received as a restricted stock unit award under a grant agreement, not as a market purchase.

What type of equity instrument did CAI grant to Joseph E. Gilliam?

The award represents restricted stock units that convert into Common Stock and vest under the applicable grant agreement. Vesting terms are governed by that agreement but are not detailed here.

Is this CAI Form 4 transaction part of a Rule 10b5-1 trading plan?

The filing’s Rule 10b5-1 checkbox is not marked as affirmatively under a plan, and the sole footnote describes vesting terms only, without indicating a 10b5-1 trading arrangement.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 08/14/2026 - 05:41 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Gilliam Joseph E

(Last) (First) (Middle)

C/O CARIS LIFE SCIENCES, INC.

750 W. JOHN CARPENTER FREEWAY, SUITE 800

(Street)

IRVING TEXAS 75039

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Caris Life Sciences, Inc. [ CAI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/14/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/14/2026		A		13,192(1)	A	$0	29,321	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents an award of restricted stock units which vest in accordance with the applicable grant agreement.

Remarks:

	/s/ J. Russel Denton, Attorney-in-Fact	08/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)